SEMAGLUTIDA E BENEFÍCIOS MEDICAMENTOSOS NO CONTEXTO CARDIOMETABÓLICO

SEMAGLUTIDE AND DRUG BENEFITS IN THE CARDIOMETABOLIC CONTEXT

Abstract

_{Semaglutide, approved in 2018, is a drug that mimics human GLP-1. It is used to treat type 2 diabetes in adults and to reduce the risk of cardiovascular events in individuals with type 2 diabetes and cardiovascular disease. In addition, it has demonstrated cardioprotective effects by reducing blood pressure and cholesterol levels. Several studies have shown that the drug is useful in the treatment of obesity when used, due to its unique mode of action. The present study aims to analyze the long-term efficacy of injectable semaglutide in the treatment of obesity in view of the benefits and risks associated with indiscriminate use. This is a narrative review of the literature, which seeks to answer questions about the efficacy of semaglutide as a treatment option for obesity and weight loss. In this way, a simple literature review was conducted using the data found in the year 2024.
Keywords: Obesity, Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists.}